Tick-Borne Encephalitis Virus IgG Control Serum BC112G

$94.00

Summary

Virion/Serion Diagnostic Kit Control for research use (RUO)
Tick-Borne Encephalitis Virus (TBEV) IgG Control Serum
Applications: ELISA
IgG control serum
Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
3 mL

SKU: BC112G Categories: control serum, Virion/Serion kits Tags: ELISA control serum, IgG, Tick-Borne Encephalitis Virus

Weight	1 lbs
Dimensions	9 × 5 × 2 in
target	Tick-Borne Encephalitis Virus reactive IgG
species reactivity	Tick-Borne Encephalitis Virus
applications	ELISA
assay type	Indirect & quantitative
available size	3 mL

Tick-Borne Encephalitis Virus IgG Control Serum BC112G

kit
Research area Infectious Disease
Storage Store at 2-8°C.
Associated products FSME/TBE (Tick-Borne Encephalitis) Virus (Premium) Antigen (BA112VS) FSME/TBE (Tick-Borne Encephalitis) Virus Antigen (BA112VSL) Tick-Borne Encephalitis Virus IgG Control Serum (BC112G) Tick-Borne Encephalitis Virus IgM Control Serum (BC112M) Tick-Borne Encephalitis Virus IgG ELISA Kit (ESR112G) Tick-Borne Encephalitis Virus IgM ELISA Kit (ESR112M)

target relevance

human antibody anti-Tick-Borne Encephalitis Virus (TBE/FSME)

Tick-Borne Encephalitis Virus (TBE/FSME)

Description
Virus that causes tick-borne encephalitis (TBE/FSME)

Structure
Tick-borne encephalitis virus (TBEV), also known as FSME virus (Frühsommer-Meningoenzephalitis virus), is an enveloped, positive-sense, single-stranded RNA virus belonging to the genus Flavivirus within the family Flaviviridae. The virus is closely related to other medically important flaviviruses, including West Nile virus, Yellow fever virus, Dengue virus, and Zika virus. TBEV is maintained in nature through transmission cycles involving ixodid ticks, primarily Ixodes ricinus and Ixodes persulcatus, and a variety of wild mammalian hosts. Three major subtypes are recognized: European, Siberian, and Far Eastern. Human infection typically occurs through the bite of an infected tick, although transmission may also occur through the consumption of unpasteurized milk or dairy products from infected animals. The virus is neurotropic and can invade the central nervous system, resulting in severe neurological disease.

Diagnosis
The diagnosis of tick-borne encephalitis virus infection is performed through serological and molecular methods. Detection of TBEV-specific IgM and IgG antibodies using ELISA is the primary laboratory approach and is considered highly sensitive and specific during the neurological phase of disease. Confirmation may be obtained using virus neutralization assays. Molecular detection by reverse transcription polymerase chain reaction (RT-PCR) may identify viral RNA during the early viremic phase but is often less useful after neurological symptoms develop because viremia is typically transient. Cerebrospinal fluid analysis frequently demonstrates pleocytosis and elevated protein concentrations in patients with central nervous system involvement. Accurate laboratory diagnosis is essential because clinical symptoms overlap with those of other viral and bacterial neurological infections.

Symptoms
Tick-borne encephalitis virus infection frequently follows a biphasic course. After an incubation period of approximately seven to fourteen days, the initial phase is characterized by nonspecific flu-like symptoms including fever, fatigue, headache, muscle aches, malaise, and nausea. Following a symptom-free interval, a second phase may occur in which the virus affects the central nervous system, resulting in meningitis, encephalitis, meningoencephalitis, or myelitis. Neurological manifestations may include severe headache, neck stiffness, confusion, impaired consciousness, tremors, paralysis, seizures, and cognitive dysfunction. While many infections remain asymptomatic or mild, severe disease can result in long-term neurological sequelae or death, particularly among older adults and patients infected with more virulent viral subtypes.

Data

FAQ & Publications

Frequently Asked Questions

What is the intended application of the Tick-Borne Encephalitis Virus IgG Control Serum BC112G?

The Tick-Borne Encephalitis Virus IgG Control Serum BC112G is designed for use as a control in ELISA assays, specifically indirect and quantitative detection of TBEV reactive IgG antibodies.

How should the Tick-Borne Encephalitis Virus IgG Control Serum BC112G be stored to maintain its stability?

This control serum should be stored at temperatures between 2 to 8 degrees Celsius to ensure proper preservation and stability.

Publications

pmid	title	authors	citation
We haven't added any publications to our database yet.

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.

Protocols

relevant to this product
BC112G protocol

Documents

#
Please enter your product and batch number here.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

Tick-Borne Encephalitis Virus IgG Control Serum BC112G

Data

FAQ & Publications

Protocols

Documents

Related Technical Resources & Posts

Reviews

Related Products

Cytomegalovirus IgG Control Serum BC109G

Brucella IgG Control Serum BC116G

Enterovirus IgG Control Serum BC133G

Borrelia burgdorferi IgG Control Serum BC121G

Echovirus IgG Control Serum BC135G

Bordetella pertussis IgG Control Serum BC120G

Echinococcus IgG Control Serum BC107G

Aspergillus fumigatus IgG Control Serum BC132G

Diphtheria IgG Control Serum BC130G

Adenovirus IgG Control Serum BC128G

Coxsackie IgG Virus Control Serum BC134G

Chlamydia trachomatis IgG Control Serum BC1372G

Chlamydia pneumoniae IgG Control Serum BC1371G

Candida albicans IgG Control Serum BC117G

Campylobacter jejuni IgG Control Serum BC139G